MetLife Investment Management’s Taysha Gene Therapies TSHA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $250K | Buy |
108,078
+367
| +0.3% | +$848 | ﹤0.01% | 2070 |
|
|
2025
Q1 | $150K | Buy |
107,711
+44,721
| +71% | +$62.2K | ﹤0.01% | 2344 |
|
|
2024
Q4 | $109K | Sell |
62,990
-13,047
| -17% | -$22.6K | ﹤0.01% | 2580 |
|
|
2024
Q3 | $153K | Buy |
76,037
+34,243
| +82% | +$68.8K | ﹤0.01% | 2428 |
|
|
2024
Q2 | $93.6K | Buy |
+41,794
| New | +$93.6K | ﹤0.01% | 2638 |
|
|
2022
Q1 | – | Sell |
-9,509
| Closed | -$111K | – | 2774 |
|
|
2021
Q4 | $111K | Hold |
9,509
| – | – | ﹤0.01% | 2374 |
|
|
2021
Q3 | $177K | Hold |
9,509
| – | – | ﹤0.01% | 2171 |
|
|
2021
Q2 | $202K | Buy |
+9,509
| New | +$202K | ﹤0.01% | 2170 |
|